Louise Chen
Stock Analyst at Scotiabank
(2.67)
# 1,921
Out of 5,162 analysts
296
Total ratings
46.98%
Success rate
2.8%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $28.57 | +40.01% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $241.52 | +9.72% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $59.08 | +1.56% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $115.61 | +3.80% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $745.77 | +3.25% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $16.40 | +387.80% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.54 | +154.24% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $29.62 | -52.73% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $2.45 | +389.82% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $22.03 | +149.66% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $64.49 | -14.72% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.00 | +200.00% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $122.06 | -59.04% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.78 | +159.52% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $34.00 | -50.00% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $17.92 | +179.02% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $8.38 | +258.00% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $18.37 | +199.40% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.58 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $37.96 | +321.50% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $54.58 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $219.68 | +9.25% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.58 | +69.30% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.98 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.06 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $985.08 | -10.16% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.98 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $24.40 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.56 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.32 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.04 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.97 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.29 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.64 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.87 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $4.74 | +1,272.76% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.68 | +86.57% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.90 | +259.71% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $22.75 | +119.78% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.18 | +129.36% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.60 | +1,400.00% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.50 | +335,486,977.53% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $205.65 | +25.46% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $0.88 | +5,572.79% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.19 | +1,580.67% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.25 | +520.69% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $28.57
Upside: +40.01%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $241.52
Upside: +9.72%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $59.08
Upside: +1.56%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $115.61
Upside: +3.80%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $745.77
Upside: +3.25%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $16.40
Upside: +387.80%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.54
Upside: +154.24%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $29.62
Upside: -52.73%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $2.45
Upside: +389.82%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $22.03
Upside: +149.66%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $64.49
Upside: -14.72%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.00
Upside: +200.00%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $122.06
Upside: -59.04%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.78
Upside: +159.52%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $34.00
Upside: -50.00%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $17.92
Upside: +179.02%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $8.38
Upside: +258.00%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.37
Upside: +199.40%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.58
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $37.96
Upside: +321.50%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $54.58
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $219.68
Upside: +9.25%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.58
Upside: +69.30%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.98
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.06
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $985.08
Upside: -10.16%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.98
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $24.40
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.56
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.32
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.04
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.97
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.29
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.64
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.87
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $4.74
Upside: +1,272.76%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.68
Upside: +86.57%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.90
Upside: +259.71%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $22.75
Upside: +119.78%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.18
Upside: +129.36%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.60
Upside: +1,400.00%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.50
Upside: +335,486,977.53%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $205.65
Upside: +25.46%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $0.88
Upside: +5,572.79%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.19
Upside: +1,580.67%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.25
Upside: +520.69%